Caspofungin/rifampicin interaction

October 2012
Reactions Weekly;10/6/2012, Issue 1422, p15
Case Study
The article describes the case of a 65-year-old woman who developed Candida (C.) parapsilosis candidaemia due to failure of treatment with caspofungin for C. lusitaniae while receiving rifampicin for Mycobacterium tuberculosis.


Related Articles

  • Ritonavir Enables Combined Therapy with Rifampin and Saquinavir. Veldkamp, A .I.; Hoetelmans, R. M. W.; Beijnen, J. H.; Mulder, J. W.; Meenhorst, P. L. // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1586 

    Examines whether ritonavir enables the treatment of coinfection by HIV-1 and Mycobacterium tuberculosis with saquinavir and rifampin. Standard of care for the treatment of HIV-1 infection; Pharmacokinetic profiles of saquinavir in patients treated with combinations of ritonavir, saquinavir and...

  • New Anti-Tuberculosis Drugs with Novel Mechanisms of Action. Riversa, Emma C.; Mancera, Ricardo L. // Current Medicinal Chemistry;2008, Vol. 15 Issue 19, p1956 

    It is estimated that a third of the world's population is currently infected with tuberculosis, leading to 1.6 million deaths annually. The current drug regimen is 40 years old and takes 6-9 months to administer. In addition, the emergence of drug resistant strains and HIV co-infection mean that...

  • Frequency of mutations in rifampicin and isoniazid resistant isolates of M. tuberculosis: an analysis from Central India. Desikan, Prabha; Kharate, Atul; Panwalkar, Nikita; Khurana, Jyoti; Mirza, Shaina Beg; Chaturvedi, Aparna; Varathe, Reeta; Chourey, Manju; Kumar, Pradeep; Doshi, Nitin; Pandey, Manoj // Germs;Dec2016, Vol. 6 Issue 4, p125 

    Background The spread of drug-resistant tuberculosis has challenged tuberculosis control strategies globally. The present study aims to analyzes the frequency of mutations in rpoB, katG and inhA genes in strains of M. tuberculosis complex (MTBC) circulating in Central India. It is anticipated...

  • Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Sch�nfeld, Nicolas; Bergmann, Thorsten; Vesenbeckh, Silvan; Mauch, Harald; Bettermann, Gudrun; Bauer, Torsten T.; R�ssmann, Holger // Lung India;Oct-Dec2012, Vol. 29 Issue 4, p309 

    Context: The treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is consistently difficult. Besides resistances, drug availability can be problematic and costs for therapy are high. Aims: Our aim was to evaluate alternatives in treatment of MDR and XDR...

  • Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. Martin, Anandi; Paasch, Fabienne; Docx, Sven; Fissette, Krista; Imperiale, Belen; Ribón, Wellman; González, Liliana Andrea; Werngren, Jim; Engström, Anna; Skenders, Girts; Juréen, Pontus; Hoffner, Sven; Del Portillo, Patricia; Morcillo, Nora; Palomino, Juan Carlos // Journal of Antimicrobial Chemotherapy (JAC);Apr2011, Vol. 66 Issue 4, p827 

    Objectives To perform a multicentre study to evaluate the performance of the colorimetric redox indicator (CRI) assay and to establish the MICs and critical concentrations of rifampicin, isoniazid, ofloxacin, kanamycin and capreomycin. Methods The study was carried out in two phases. Phase I...

  • Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. Schön, Thomas; Juréen, Pontus; Giske, Christian G.; Chryssanthou, Erja; Sturegård, Erik; Werngren, Jim; Kahlmeter, Gunnar; Hoffner, Sven E.; Ängeby, Kristian A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2009, Vol. 64 Issue 4, p786 

    Objectives: The aim of this study was to establish wild-type MIC distributions of first-line drugs for Mycobacterium tuberculosis, as well as to explore the usefulness of such distributions when setting clinical breakpoints.

  • NEW STRATEGIES FOR THE TREATMENT OF TUBERCULOSIS. Birluţiu, Victoria; Mitrea, Mirela // Therapeutics, Pharmacology & Clinical Toxicology;2009, Vol. 13 Issue 4, p370 

    The treatment of Tuberculosis may be associated with an emergence of mycobacterial resistance through chromosomal alterations, but also through a poor administration of treatment, leading to the emergence of multi-drug-resistant strains MDR-TB or extensively drug-resistant, XDR-TB, responsible...

  • Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso. Sangaré, L.; Diandé, S.; Kouanda, S.; Dingtoumda, B. I.; Mourfou, A.; Ouédraogo, F.; Sawadogo, I.; Nébié, B.; Gueye, A.; Sawadogo, L. T.; Traoré, A. S. // Annals of African Medicine;2009, Vol. 8 Issue 3, p15 

    Background: Tuberculosis drug-resistance becomes common in sub-Saharan Africa; however, very few data are available in Burkina Faso. The aim of this study is to assess the acquired resistance of Mycobacterium tuberculosis complex strains identified in TB patients to four first-line drugs in...

  • Derivatives of 3-Isoxazolecarboxylic Acid Esters - A Potent and Selective Compound Class against Replicating and Nonreplicating Mycobacterium tuberculosis. Lilienkampf, Annamaria; Pieroni, Marco; Franzblau, Scott G.; Bishai, William R.; Kozikowski, Alan P. // Current Topics in Medicinal Chemistry;Apr2012, Vol. 12 Issue 7, p729 

    New antituberculosis (anti-TB) drugs are urgently needed to battle drug-resistant Mycobacterium tuberculosis (Mtb) strains and to shorten the long treatment regimen. A series of isoxazole-based compounds, bearing a carboxy moiety at the C3 position, are highly potent and versatile anti-TB...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics